Goldberg & Osborne Report Lawsuits On The Rise as Bladder Cancer Becomes a Dangerous Side Effect of Actos

    PHOENIX, AZ, August 13, 2011 /24-7PressRelease/ -- Actos (pioglitazone) and several other drugs in the same family such as Actoplus Met, Actoplus Met XR, and Duetact have been implicated in a rising number of bladder cancer cases among type 2 diabetics. The Actos group of medications is often introduced as a diabetes preventative in the earliest stages of the disease.

The FDA released a safety announcement on June 15, 2011 warning patients and their physicians about the increased bladder cancer risk associated with Actos use. Although the drug has not been taken off of the market in the United States, its use has been suspended in France and is no longer recommended to new patients in Germany. The FDA claims it is continuing an extensive investigation of the drug which began in September 2010.

Those who take Actos for more than a year to manage their blood glucose levels are at least 40% more at risk for developing bladder cancer than the general population. It appears that the longer Actos has been taken by the patient, the higher the risk. Men are at higher risk than women.

The symptoms of bladder cancer can be mistaken for urinary tract infections, leading to late diagnosis. Frequent urination and painful urination are common. Blood may be present in the urine giving it a brown or orange color.

Goldberg & Osborne encourages anyone who has bladder cancer and has managed their diabetes by taking Actos (pioglitazone), Actoplus Met , Actoplus Met XR , or Duetact to call (800) 549-8048 for a free consultation. Lawsuits against manufacturer Takeda Pharmaceuticals have been filed in California and Pennsylvania. The personal injury attorneys at Goldberg & Osborne are committed to helping victims of Actos-related bladder cancer receive the compensation they deserve. Please visit our website for more information: http://1800theeagle.com/practice-areas/dangerous-drugs/actos/.

# # #